Scott Praill's Contact Details

Scott Praill's Company Details

Kintara Therapeutics, Inc. NASDAQ: KTRA

San Diego, California, United States • 7 Employees
Research

Our Fight Against CancerKintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs.Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.A Pipeline of Breakthrough Cancer TherapeuticsVAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.VAL-083's indications include:Glioblastoma Multiforme (GBM)Ovarian CancerPediatric CNS TumorsREM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.REM-001's indications include:Cutaneous Metastatic Breast CancerRecurrent Basal Cell Carcinoma Nevus SyndromeHemodialysis Arteriovenous (AV) Access